CASI Pharmaceuticals (CASI) Gains from Investment Securities (2022 - 2025)
Historic Gains from Investment Securities for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $111000.0.
- Pharmaceuticals' Gains from Investment Securities fell 9403.55% to $111000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $4.9 million, marking a year-over-year increase of 2754.73%. This contributed to the annual value of $2.0 million for FY2024, which is 957.39% up from last year.
- As of Q2 2025, Pharmaceuticals' Gains from Investment Securities stood at $111000.0, which was down 9403.55% from $2.0 million recorded in Q4 2024.
- In the past 5 years, Pharmaceuticals' Gains from Investment Securities registered a high of $2.9 million during Q4 2023, and its lowest value of -$1.6 million during Q1 2022.
- Its 4-year average for Gains from Investment Securities is $336454.5, with a median of $10000.0 in 2023.
- Examining YoY changes over the last 5 years, Pharmaceuticals' Gains from Investment Securities showed a top increase of 635000.0% in 2023 and a maximum decrease of 9856.32% in 2023.
- Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$46000.0 in 2022, then soared by 6350.0% to $2.9 million in 2023, then tumbled by 31.13% to $2.0 million in 2024, then crashed by 94.39% to $111000.0 in 2025.
- Its Gains from Investment Securities was $111000.0 in Q2 2025, compared to $2.0 million in Q4 2024 and $1.9 million in Q2 2024.